A Watertown biotech says is received a $112 million investment led by the investment firm that manages the assets of the Novo ...

Novo is in a strong financial position to continue its exploration focus on Western Australia and Victoria, with no debt and ...

AvenCell Therapeutics, Inc. ("AvenCell"), a leading clinical-stage cell therapy company focused on advancing both autologous and allogeneic switchable CAR-T cell therapies, today announced that it has ...

AvenCell Therapeutics has secured $112 million in series B funds as the Novo Holdings-backed biotech seeks clinical proof ...

Booster Therapeutics has announced its inception to develop a new class of proteasome activator medicines for ...

US clinical-stage biotech AvenCell Therapeutics announced that it has raised $112 million in Series B financing, which was ...

Novo’s 2024 Sustainability Report demonstrates that Novo remains committed to sustainability as we execute our exploration ...

The boom experienced by the weight loss drug market comes as little surprise when considering that almost a third of the ...

Booster Therapeutics launched today with the support of a $15 million financing led by investors Apollo Health Ventures and ...

Discover Booster Therapeutics' novel 20S proteasome activation approach to neurodegenerative diseases as it launches with $15 ...